BioCryst Appoints New Chief Medical Officer
Ticker: BCRX · Form: 8-K · Filed: Jun 13, 2024 · CIK: 882796
Sentiment: neutral
Topics: executive-appointment, personnel, pipeline
Related Tickers: SRPT
TL;DR
BioCryst snagged a new CMO from Sarepta to push their pipeline forward.
AI Summary
BioCryst Pharmaceuticals, Inc. announced on June 12, 2024, the appointment of Dr. William P. Sheridan as Chief Medical Officer. Dr. Sheridan previously served as Executive Vice President and Chief Medical Officer at Sarepta Therapeutics, Inc. This appointment is part of BioCryst's ongoing efforts to advance its pipeline, particularly its oral Factor D inhibitor, BCX9947.
Why It Matters
The appointment of a new Chief Medical Officer can signal a strategic shift or renewed focus on clinical development and regulatory pathways for BioCryst's drug candidates.
Risk Assessment
Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding strategic direction and execution, though the specific individual's background may mitigate some risk.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- Dr. William P. Sheridan (person) — Appointed Chief Medical Officer
- Sarepta Therapeutics, Inc. (company) — Previous employer of Dr. Sheridan
- BCX9947 (drug_candidate) — Pipeline drug mentioned
FAQ
When was Dr. William P. Sheridan appointed as Chief Medical Officer?
Dr. William P. Sheridan was appointed as Chief Medical Officer on June 12, 2024.
What was Dr. Sheridan's previous role?
Dr. Sheridan previously served as Executive Vice President and Chief Medical Officer at Sarepta Therapeutics, Inc.
What is the significance of this appointment for BioCryst's pipeline?
The appointment is part of BioCryst's ongoing efforts to advance its pipeline, specifically mentioning its oral Factor D inhibitor, BCX9947.
What is BioCryst Pharmaceuticals, Inc.'s principal executive office address?
BioCryst Pharmaceuticals, Inc.'s principal executive offices are located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
What is the filing date of this Form 8-K?
This Form 8-K was filed on June 13, 2024.
Filing Stats: 776 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2024-06-13 16:23:55
Filing Documents
- f8k_061324.htm (8-K) — 34KB
- exh_101.htm (EX-10.1) — 129KB
- 0001171843-24-003430.txt ( ) — 364KB
- bcrx-20240612.xsd (EX-101.SCH) — 3KB
- bcrx-20240612_lab.xml (EX-101.LAB) — 33KB
- bcrx-20240612_pre.xml (EX-101.PRE) — 22KB
- f8k_061324_htm.xml (XML) — 4KB
02. Departure of Directors or Certain Officers; Election of Directors; Appointment
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 12, 2024, at the 2024 Annual Meeting of Stockholders (the "Annual Meeting") of BioCryst Pharmaceuticals, Inc. (the "Company"), the Company's stockholders approved, by the affirmative vote of a majority of the shares of the Company's common stock represented in person or by proxy at the Annual Meeting and voting on the proposal, a proposal to amend and restate the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (such plan, as amended and restated, the "Stock Incentive Plan"), increasing the number of shares available for issuance under the Stock Incentive Plan by 7,000,000 shares (the "Incentive Plan Proposal"). A detailed description of the Stock Incentive Plan is included in the Company's Definitive Proxy Statement for the Annual Meeting. The description of the Stock Incentive Plan in this report does not purport to be complete and is qualified in its entirety by reference to the full text of the Stock Incentive Plan, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. The Annual Meeting was held on June 12, 2024 for the purpose of (1) electing three directors to serve for a term ending at the Company's 2027 annual meeting of stockholders and until a successor is duly elected and qualified; (2) ratifying the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2024; (3) holding an advisory vote approving the Company's executive compensation; and (4) approving the Incentive Plan Proposal described in Item 5.02 above. The nominees for director were elected by the following votes: FOR WITHHELD Nancy J. Hutson, Ph.D. 124,478,890 20,918,007 Vincent J. Milano 141,143,460 4,253,437 A. Machelle Sanders 141,189,098 4,207,799 In addition, there were 26,962,524 broker non-votes for each director. The proposed ratification of the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2024 was approved by the following votes: FOR 167,496,029 AGAINST 3,932,954 ABSTAIN 930,438 The proposed advisory resolution regarding executive compensation was approved by the following votes: FOR 138,402,008 AGAINST 6,410,647 ABSTAIN 584,242 BROKER NON-VOTES 26,962,524 The Incentive Plan Proposal was approved by the following votes: FOR 101,846,368 AGAINST 43,055,807 ABSTAIN 494,722 BROKER NON-VOTES 26,962,524 There was no other business voted upon at the Annual Meeting.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 22, 2024) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 13, 2024 BioCryst Pharmaceuticals, Inc. By: /s/ Alane Barnes Alane Barnes Chief Legal Officer